Physician profile
Seth M Assar
NPI 1396096939
$1,315.07
in general payments reported to CMS, 2019-2025
19 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.10 · 2020: $58.26 · 2021: $47.60 · 2022: $38.14 · 2023: $334 · 2024: $159 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.97 |
| Education | $190.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $224.75 | 2023 | |
| Astellas Pharma US INC | $215.65 | 2024-2025 | Ambisome |
| Glaxosmithkline, LLC. | $163.01 | 2020-2025 | Nucala, Trelegy Ellipta |
| Abiomed | $149.99 | 2025 | |
| Electromed, INC. | $83.28 | 2024-2025 | Smartvest |
| Insmed, INC. | $75.12 | 2025 | Arikayce |
| Genzyme Corporation | $67.16 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $59.54 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $49.78 | 2019-2023 | Imfinzi, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.86 | 2023-2025 | |
| Grifols USA, LLC | $34.20 | 2020-2024 | Prolastin-C Liquid |
| Viatris Specialty LLC | $29.74 | 2025 | Yupelri |
| Pulmonx Corporation | $26.34 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $19.50 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $17.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.18 | 2025 | Tezspire |
| Baxter Healthcare | $15.18 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $14.46 | 2023 | Recarbrio, Zerbaxa |
| 3b Medical, INC. | $9.88 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Assar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.